Our mission is to discover and develop innovative therapies to transform the lives of people with rare central nervous system disorders.
Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen’s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers.
Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.
More information at www.lysogene.com
Founded in 2009 by Karen Aiach, whose own child was affected by a neurodegenerative disease, Lysogene is rooted in a deep and compassionate understanding of the impact these diseases have on patients and families. Karen’s personal experience fuels her determination to deliver real solutions that will improve patient outcomes and enhance quality of life for both patients and caregivers.
Over the past 10 years, Lysogene has acquired deep experience in developing gene therapies—from early discovery through the clinical, registration and review phases. Our strong science and execution track record has been validated by our partnership with Sarepta Therapeutics and the support of top-tier investors, with nearly $100m raised since inception.
More information at www.lysogene.com
Location: France, Ile-de-France, Neuilly-sur-Seine
Employees: 11-50
Phone: +33 1 41 43 03 90
Total raised: $27.34M
Founded date: 2009
Investors 1
| Date | Name | Website |
| - | Sofinnova ... | sofinnovap... |
Funding Rounds 2
| Date | Series | Amount | Investors |
| 26.11.2021 | - | $4.85M | - |
| 23.05.2014 | Series A | $22.49M | - |
Mentions in press and media 7
| Date | Title | Description |
| 26.11.2021 | Lysogene S.A. Secures EUR 4.3 Million Non-Dilutive Financing from Bpifrance to Support its Development | Lysogene S.A. announced that it has secured a EUR 4.3 million non-dilutive financing from Bpifrance. This financing consists of a EUR 3.0 million R&D innovation loan to finance the clinical study of LYS-GM101 drug candidate for the trea... |
| 30.08.2021 | Lysogene : Announces First Patient in the United States Dosed with LYS-GM101 Investigational Gene Therapy for the Treatment of GM1 Gangliosidosis | Second patient treated in the global adaptative-design clinical trial with LYS-GM101 Ongoing enrollment of a total of 16 patients in the UK, US and France Paris, France - 30 August 2021 at 08:00 am CET - Lysogene (FR0013233475 - LYS), a pha... |
| 09.03.2021 | How Covid-19 is changing rare diseases research | Twenty years after researchers published their first discoveries associated with human genome sequencing, policymakers are fighting to overcome obstacles that hobble the potential of genetic medicine to recognize, diagnose and cure rare dis... |
| 22.01.2015 | Regenxbio nets $30M to bring its gene therapy to clinical trial | Here’s how it works: In Hurler syndrome, for instance, children don’t carry a gene that develops an enzyme called IDUA that breaks down complex sugars. These build up, and ultimately impair mental development, organ function, physical abili... |
| 23.05.2014 | Lysogene Raises €16.5M in Series A Funding | Lysogene, a Paris, Germany-based gene therapy company, raised €16.5m in Series A funding. The round was led by Sofinnova Partners, with participation from Bpifrance‘s Innobio fund and Novo Seeds, which is part of Novo A/S. In conjunction wi... |
| - | How Covid-19 is changing rare diseases research | Twenty years after researchers published their first discoveries associated with human genome sequencing, policymakers are fighting to overcome obstacles that hobble the potential of genetic medicine to recognize, diagnose and cure rare dis... |
| - | Regenxbio nets $30M to bring its gene therapy to clinical trial | Washington, D.C.-based gene therapy outfit Regenxbio just raised $30 million to bring its platform into the clinic. The dollars will help Regenxbio generate clinical proof of concept data, as well as work toward in-licensing new programs. T... |